Colossal Biosciences Clones NFL Star's Dog, Eyes Extinct Species Revival
Colossal Biosciences, a Texas-based bioengineering firm founded in 2021, has made waves in the pet cloning industry. The company, valued at $10.2 billion, recently acquired Viagen Pets and Equine, known for cloning celebrity pets like Barbra Streisand's dog Samantha and Paris Hilton's Chihuahua, Diamond Baby.
Colossal Biosciences was established by Ben Lamm and George Church in 2021. The company specializes in pet cloning technology and has recently demonstrated its capabilities by cloning NFL star Tom Brady's late dog, Lua. Brady revealed in an interview with People magazine that his new dog, Junie, is a clone of Lua, created using non-invasive pet cloning techniques before Lua's passing.
The company's ambitious goals extend beyond pet cloning. Colossal Biosciences aims to use genetic engineering to revive extinct species. The dire wolf and the dodo bird are among the species the company hopes to bring back to life.
Colossal Biosciences, with its $10.2 billion valuation, is at the forefront of pet cloning technology. Following the acquisition of Viagen Pets and Equine and the successful pet cloning of Tom Brady's dog, the company looks to the future, aiming to revive extinct species through genetic engineering.
